UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Apr

    28

    UCB Announces PDUFA Date for Bimekizumab

    Apr

    23

    "The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

    Apr

    23

    UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

    UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 

    Apr

    23

    UCB Showcases Approach to Creating Patient Value in Immuno-Dermatology

    At UCB, we have come to develop a deep understanding of the patient experience and the unmet needs of people living with immuno-dermatological conditions. As we join for the American Academy of Dermatology VMX 2021 Conference, read from Rhonda Peebles, our Head of U.S. Dermatology, on UCB’s approach to creating value for patients.